Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin

Detalhes bibliográficos
Autor(a) principal: Vieira, Ana P.
Data de Publicação: 2017
Outros Autores: Pimenta, Andreia, Silva, Diana, Gil, Maria, Alves, Patrícia, Coimbra, Patrícia, Mata, José, Bozukova, Dimitriya, Correia, Tiago R., Correia, Ilídio Joaquim Sobreira, Serro, Ana Paula, Guiomar, António
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.6/4707
Resumo: Endophthalmitis, an inflammation of the eye due to perioperative infection, may occur after cataract surgery. Intraocular lenses (IOLs) loaded with an antibiotic have been proposed as an alternative to the conventional postoperative endophthalmitis prophylaxis, since the antibiotic is delivered directly to the target site. In this work, an IOL-based antibiotic releasing system was prepared from a copolymer used in the production of IOLs and a fluoroquinolone used in endophthalmitis prophylaxis (moxifloxacin, MFX). Argon plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA) in the presence of MFX was the approach selected for surface modification, with MFX loaded both by entrapment in the grafted polyHEMA coating and by soaking. Surface and bulk properties were evaluated before and after surface modification and the MFX release profiles were obtained both in batch mode (sink conditions) and under hydrodynamic conditions, employing a purpose-built microfluidic cell, which simulated the hydrodynamic conditions around the eye lens. The effect of storage on the release profile of the best system was also assessed. The best system released MFX for ca. 15 days above the minimum inhibitory concentration for Staphylococcus aureus and Staphylococcus epidermidis. The released MFX showed antimicrobial activity against these bacteria and was non-cytotoxic against corneal endothelial cells.
id RCAP_9c0330f996f7c7335d5cdedebbe2cd95
oai_identifier_str oai:ubibliorum.ubi.pt:10400.6/4707
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacinCataractEndophthalmitisIntraocular lensControlled releaseMoxifloxacinPlasma graftingArgon2-hydroxyethyl methacrylateEndophthalmitis, an inflammation of the eye due to perioperative infection, may occur after cataract surgery. Intraocular lenses (IOLs) loaded with an antibiotic have been proposed as an alternative to the conventional postoperative endophthalmitis prophylaxis, since the antibiotic is delivered directly to the target site. In this work, an IOL-based antibiotic releasing system was prepared from a copolymer used in the production of IOLs and a fluoroquinolone used in endophthalmitis prophylaxis (moxifloxacin, MFX). Argon plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA) in the presence of MFX was the approach selected for surface modification, with MFX loaded both by entrapment in the grafted polyHEMA coating and by soaking. Surface and bulk properties were evaluated before and after surface modification and the MFX release profiles were obtained both in batch mode (sink conditions) and under hydrodynamic conditions, employing a purpose-built microfluidic cell, which simulated the hydrodynamic conditions around the eye lens. The effect of storage on the release profile of the best system was also assessed. The best system released MFX for ca. 15 days above the minimum inhibitory concentration for Staphylococcus aureus and Staphylococcus epidermidis. The released MFX showed antimicrobial activity against these bacteria and was non-cytotoxic against corneal endothelial cells.ElsevieruBibliorumVieira, Ana P.Pimenta, AndreiaSilva, DianaGil, MariaAlves, PatríciaCoimbra, PatríciaMata, JoséBozukova, DimitriyaCorreia, Tiago R.Correia, Ilídio Joaquim SobreiraSerro, Ana PaulaGuiomar, António2018-03-22T10:21:17Z2017-08-162017-08-16T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.6/4707engVieira, A. P., Pimenta, A. F., Silva, D., Gil, M. H., Alves, P., Coimbra, P., Mata, J. L. G. C., Bozukova, D., Correia, T. R., Correia, I.J., Serro, A. P. e Guiomar, A. J. (2017). “Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin.” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 120, pp.52-62.10.1016/j.ejpb.2017.08.006metadata only accessinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-15T09:42:01Zoai:ubibliorum.ubi.pt:10400.6/4707Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:45:45.471413Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
title Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
spellingShingle Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
Vieira, Ana P.
Cataract
Endophthalmitis
Intraocular lens
Controlled release
Moxifloxacin
Plasma grafting
Argon
2-hydroxyethyl methacrylate
title_short Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
title_full Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
title_fullStr Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
title_full_unstemmed Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
title_sort Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin
author Vieira, Ana P.
author_facet Vieira, Ana P.
Pimenta, Andreia
Silva, Diana
Gil, Maria
Alves, Patrícia
Coimbra, Patrícia
Mata, José
Bozukova, Dimitriya
Correia, Tiago R.
Correia, Ilídio Joaquim Sobreira
Serro, Ana Paula
Guiomar, António
author_role author
author2 Pimenta, Andreia
Silva, Diana
Gil, Maria
Alves, Patrícia
Coimbra, Patrícia
Mata, José
Bozukova, Dimitriya
Correia, Tiago R.
Correia, Ilídio Joaquim Sobreira
Serro, Ana Paula
Guiomar, António
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv uBibliorum
dc.contributor.author.fl_str_mv Vieira, Ana P.
Pimenta, Andreia
Silva, Diana
Gil, Maria
Alves, Patrícia
Coimbra, Patrícia
Mata, José
Bozukova, Dimitriya
Correia, Tiago R.
Correia, Ilídio Joaquim Sobreira
Serro, Ana Paula
Guiomar, António
dc.subject.por.fl_str_mv Cataract
Endophthalmitis
Intraocular lens
Controlled release
Moxifloxacin
Plasma grafting
Argon
2-hydroxyethyl methacrylate
topic Cataract
Endophthalmitis
Intraocular lens
Controlled release
Moxifloxacin
Plasma grafting
Argon
2-hydroxyethyl methacrylate
description Endophthalmitis, an inflammation of the eye due to perioperative infection, may occur after cataract surgery. Intraocular lenses (IOLs) loaded with an antibiotic have been proposed as an alternative to the conventional postoperative endophthalmitis prophylaxis, since the antibiotic is delivered directly to the target site. In this work, an IOL-based antibiotic releasing system was prepared from a copolymer used in the production of IOLs and a fluoroquinolone used in endophthalmitis prophylaxis (moxifloxacin, MFX). Argon plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA) in the presence of MFX was the approach selected for surface modification, with MFX loaded both by entrapment in the grafted polyHEMA coating and by soaking. Surface and bulk properties were evaluated before and after surface modification and the MFX release profiles were obtained both in batch mode (sink conditions) and under hydrodynamic conditions, employing a purpose-built microfluidic cell, which simulated the hydrodynamic conditions around the eye lens. The effect of storage on the release profile of the best system was also assessed. The best system released MFX for ca. 15 days above the minimum inhibitory concentration for Staphylococcus aureus and Staphylococcus epidermidis. The released MFX showed antimicrobial activity against these bacteria and was non-cytotoxic against corneal endothelial cells.
publishDate 2017
dc.date.none.fl_str_mv 2017-08-16
2017-08-16T00:00:00Z
2018-03-22T10:21:17Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.6/4707
url http://hdl.handle.net/10400.6/4707
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Vieira, A. P., Pimenta, A. F., Silva, D., Gil, M. H., Alves, P., Coimbra, P., Mata, J. L. G. C., Bozukova, D., Correia, T. R., Correia, I.J., Serro, A. P. e Guiomar, A. J. (2017). “Surface modification of an intraocular lens material by plasma-assisted grafting with 2-hydroxyethyl methacrylate (HEMA), for controlled release of moxifloxacin.” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 120, pp.52-62.
10.1016/j.ejpb.2017.08.006
dc.rights.driver.fl_str_mv metadata only access
info:eu-repo/semantics/openAccess
rights_invalid_str_mv metadata only access
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136354580299776